Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

331P - Predicting outcomes following colorectal cancer resection: Using real-world data to empower adjuvant treatment decision making

Date

10 Sep 2022

Session

Poster session 07

Topics

Cancer Intelligence (eHealth, Telehealth Technology, BIG Data)

Tumour Site

Colon and Rectal Cancer

Presenters

Adam Pennycuick

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

A. Pennycuick1, H. Selway1, J.J.M. Lam2, K.H. Khan3

Author affiliations

  • 1 Ucl Respiratory, UCL - University College London, WC1E 6BT - London/GB
  • 2 Department Of Oncology, UCLH - University College London Hospitals NHS Foundation Trust, NW1 2PG - London/GB
  • 3 Medical Oncology Department, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 331P

Background

Guidelines advocate adjuvant therapy for selected patients with resected stage II-III colorectal cancer. Risks however remain poorly defined. ESMO guidelines describe 5-year survival after resection alone of 68-83% for stage II and 45-65% for stage III; rates can be improved by 3-5% in high-risk stage II colon cancer and 10-15% in stage III with 5FU, and a further 4-5% with oxaliplatin. These windows are wide and do not take many patient factors into account. Informed decision making with discussion of the risk to benefit ratio of chemotherapy is paramount. Grade 3-4 toxicities can occur in as many as 25-55% of patients, depending on regimen and duration of treatment. Such wide ranges make balancing potential benefit and risk very challenging. In breast cancer, the widely used PREDICT online tool allows clinicians and patients to quantitively evaluate risk in a simple and user-friendly manner. There is a clear need for a similar tool in GI oncology.

Methods

The CORECT-R database is a curated, linked dataset of over 600,000 patients with colorectal cancer in England. Data is available on patient and tumour characteristics, treatments and outcomes. Using overall survival as our primary outcome we performed Cox proportional hazards modelling to compare patients receiving chemotherapy with those who did not. Multivariate modelling including both patient factors, such as age and frailty, and tumour factors, such as staging information, was used. A prototype web interface to view these data was built.

Results

We present a prototype web-based tool to predict the benefits of adjuvant chemotherapy, with appropriate confidence intervals, based on a large dataset of real-world data.

Conclusions

Quantitative, user-friendly tools such as PREDICT are invaluable for empowering patients to make informed decisions regarding adjuvant treatment. Here we use real-world data at unprecedented scale to provide a proof-of-concept tool for colorectal cancer. Following further validation, this could be transformative for adjuvant treatment decision making.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.